2021 Advances in Precision Medicine Seminar Series - Irving Institute for Clinical and Translational Research/CTSA
"AAV Gene Therapy as a New Paradigm in Medicine – State Of-the Art, Challenges and Strategies for Mitigation"
Guangping Gao, PhD
Professor of Microbiology and Physiological Systems
Penelope Booth Rockwell Professor in Biomedical Research
Director, Horae Gene Therapy Center and Viral Vector Core
Co-Director, Li Weibo Institute for Rare Diseases Research
University of Massachusetts Medical School
Dr. Guangping Gao is an internationally recognized gene therapy researcher, instrumental in the discovery and characterization of a new family of adeno-associated virus (AAV) serotypes, which revitalized the field of gene therapy. Dr. Gao’s research primarily focuses on gene therapy platform technologies and product development.
Dr. Gao has published more 310+ research papers, 6 book chapters, and 5 edited books. Dr. Gao holds 191 patents with 401 more patent applications pending. He serves as Executive Editor-In-Chief of Human Gene Therapy, Senior Editor of the Gene and Cell Therapy book series, Associate Editor of Signal Transduction and Targeted Therapy, and on Editorial Boards of several other gene therapy and virology journals. Dr. Gao was ranked as the World Top 20 Translational Researchers by Nature Biotechnology. Dr. Gao co-founded Voyager Therapeutics, Adrenas Therapeutics, and Aspa Therapeutics, focusing on developing rAAV gene therapeutics for treating a variety of devastating rare diseases. Dr. Gao is an elected fellow of both the US National Academy of Inventors (NAI) and American Academy of Microbiology; Past president, American Society of Gene and Cell Therapy.
Virtual seminar via Zoom - Registration is Required (Must register with UNI)
This event is supported in part by a gift from Pfizer to Columbia University
